Two prominent keynote speakers, James C. Greenwood, President and CEO of the Biotechnology Industry Organization (BIO) and G. Steven Burrill, Founder and CEO of Burrill & Company, will headline the Life Science Innovation Northwest 2011 conference, scheduled for March 2-3 at the Washington State Convention Center in Seattle. In addition to delegations expected from more than ten countries, six panels and 60 presentations by public and private companies, and non-profit and research organizations specializing in medical technology, diagnostics, therapeutic innovations, and cutting-edge developments in global health make Life Science Innovation Northwest (LSINW) 2011 the region’s preeminent life science conference.
“We’re honored to have two of the most well-respected life science executives keynote this year’s Life Science Innovation Northwest conference,” said Chris E. Rivera, President, Washington Biotechnology & Biomedical Association (WBBA). “Under Jim’s leadership, BIO continues to foster innovation in and grow the life sciences industry worldwide through advocacy, business development and communications. We also are very pleased to again partner with Burrill & Company to host the conference and we look forward to Steve’s compelling discussion of the latest in the economic and development trends in the industry, which will draw examples from Biotech 2011, his 25th anniversary annual report on the state of the biotech industry.”
“We are delighted to be associated with the WBBA to stage this important event,” said G. Steven Burrill, CEO, Burrill & Company, a diversified global financial services firm focused on the life sciences industry. “The Pacific Northwest is a vibrant hub for biotechnology and life sciences innovation and these sectors are rapidly evolving as major economic drivers for the region. The conference will be a great opportunity to discover and interact with this community firsthand.”
James C. Greenwood was appointed President and CEO of BIO in January 2005. BIO, located in Washington, D.C., represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. Under Mr. Greenwood’s leadership, BIO has expanded its reputation as a world class advocacy organization, playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. Previously Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from 1993 through 2005 after serving in the Pennsylvania state legislature for twelve years. While in Congress, he authored numerous bills signed into law, including legislation to promote pediatric labeling for pharmaceuticals, reform medical device review and approval, and expand research and establish innovative programs to address traumatic brain injury.
G. Steven Burrill, Founder and CEO of Burrill & Company, has been involved in the growth and prosperity of the biotechnology industry for more than 40 years. He is an internationally recognized spokesperson and author for the life science and high technology industries. An early pioneer, Mr. Burrill is one of the original architects of the industry and is one of its most avid and sustained developers. He currently serves on the Boards of Directors of eight companies. Prior to founding Burrill & Company in 1994, Mr. Burrill spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, he was recognized as the biotech investment visionary by the prestigious Scientific American magazine.
The Pacific Northwest has emerged as one of the world’s most innovative and important life science sectors. Now in its eleventh year, LSINW is expanding its reach to attract more investment and partnering representatives from outside the United States and is expecting participation from delegations from Asia, India, Australia, Scandinavia, Canada, France, and Germany. These delegations provide opportunities to explore financial and strategic partnerships and investments with companies that attend and present at the conference.
About LSINW 2011
Life Science Innovation Northwest 2011 is presented by The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company. For more information on the LSINW 2011 conference, please visit www.washbio.org.
Don’t miss the multiple opportunities to position your company at LSINW!
Register now to take advantage of early-bird registration rates. Or take advantage of a 20% discount on registration if you plan to attend both the Life Science Innovation Northwest 2011 and BioPartnering North America™.
LSINW 2011 would not be possible without the support of our sponsors and partners. Thank you to the following sponsors: K&L Gates, Fenwick & West LLP, SightLife, Wells Fargo Insurance Services, Perkins Coie, and PraxAir as well as to our partners: Life Sciences British Columbia, Montana BioScience Alliance, and Oregon Bioscience Association.
Opportunities for sponsorship are still available. If you are interested in being a sponsor, please contact Stacie Byars at firstname.lastname@example.org or 206.732.6705.
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: from breakthrough discoveries to better health solutions. Learn more about the WBBA at www.washbio.org.
About Burrill & Company
Burrill & Company has established unrivaled access and visibility in the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking and media. A unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. (www.burrillandco.com).Business Wire
Last updated on: 22/01/2011